Dextran-b-poly(L-histidine) copolymer nanoparticles for pH-responsive drug delivery to tumor cells

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3197-3207

  Hwang, Jong Ho ^a,b   Choi, Cheol Woong ^a   Kim, Hyung Wook ^a   Kim, Do Hyung ^c   Kwak, Tae Won ^c   Lee, Hye Myeong ^c   Kim, Cy Hyun ^c   Chung, Chung Wook ^c   Jeong, Young Il ^c   Kang, Dae Hwan ^a,c  

^a Pusan National University School of Medicine   (South Korea)

^b Busan Medical Center   (South Korea)

^c Yangsan Hospital   (South Korea)

Author keywords

Block copolymer; Dextran; Nanoparticles; pH responsive drug targeting; Poly(L histidine)

Indexed keywords

COPOLYMER; DEXTRAN B POLY(LEVO HISTIDINE); DOXORUBICIN; NANOPARTICLE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CELL VIABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; NANOPHARMACEUTICS; PARTICLE SIZE; PH; PRECIPITATION; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL;

BLOCK COPOLYMER; DEXTRAN; NANOPARTICLES; PH-RESPONSIVE DRUG TARGETING; POLY(L-HISTIDINE);

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DEXTRANS; DOXORUBICIN; DRUG CARRIERS; HISTIDINE; HUMANS; HYDROGEN-ION CONCENTRATION; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; POLYMERS;

EID: 84883042784     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S49459     Document Type: Article

References (36)

1. Box C, Rogers SJ, Mendiola M, Eccles SA. Tumor-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol. 2010;20:128-138.
2. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem. 2013;59:85-93.
3. Zhao G, Rodriguez BL. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int J Nanomedicine. 2013;8:61-71.
4. Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, Gillies RJ. Imaging pH and metastasis. NMR Biomed. 2011;24:582-591.
5. Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011;8:2032-2038.
6. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994;54:6517-6525.
7. Shi Q, Le X, Wang B, et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 2001;20: 3751-3756.
8. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan Jones RD. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem. 2008;283:20473-20483.
9. Xu L, Fidler IJ. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res. 2000;60: 4610-4616.
10. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther. 2006;5:1275-1279.
11. Chilkoti A, Dreher MR, Meyer DE, Raucher D. Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev. 2002;54: 613-630.
12. Wahajuddin, Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine. 2012;7: 3445-3471.
13. He C, Zhuang X, Tang Z, Tian H, Chen X. Stimuli-sensitive synthetic polypeptide-based materials for drug and gene delivery. Adv Healthc Mater. 2012;1:48-78.
14. Colson YL, Grinstaff MW. Biologically responsive polymeric nanoparticles for drug delivery. Adv Mater. 2012;24:3878-3886.
15. Pack DW, Putnam D, Langer R. Design of imidazole-containing endosomolytic biopolymers for gene delivery. Biotechnol Bioeng. 2000;67:217-223.
16. Putnam D, Zelikin AN, Izumrudov VA, Langer R. PolyhistidinePEG:DNA nanocomposites for gene delivery. Biomaterials. 2003;24: 4425-4433.
17. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49:4373-4384.
18. Liu R, Li D, He B, et al. Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles. J Control Release. 2011;152:49-56.
19. Johnson RP, Chung CW, Jeong YI, Kang DH, Suh H, Kim I. Poly(Lhistidine)-tagged 5-aminolevulinic acid prodrugs: new photosensitizing precursors of protoporphyrin IX for photodynamic colon cancer therapy. Int J Nanomedicine. 2012;7:2497-2512.
20. Johnson RP, Jeong YI, Choi E, et al. Biocompatible poly(2-hydroxyethyl methacrylate)-b-poly(L-histidine) hybrid materials for pH-sensitive intracellular anticancer drug delivery. Adv Funct Mater. 2012;22: 1058-1068.
21. Jeong YI, Kim DH, Chung CW, et al. Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-coglycolide) copolymer. Int J Nanomedicine. 2011;6:1415-1427.
22. Asayama S, Sudo M, Nagaoka S, Kawakami H. Carboxymethyl poly(Lhistidine) as a new pH-sensitive polypeptide to enhance polyplex gene delivery. Mol Pharm. 2008;5:898-901.
23. Liu R, He B, Li D, et al. Effects of pH-sensitive chain length on release of doxorubicin from mPEG-b-PH-b-PLLA nanoparticles. Int J Nanomedicine. 2012;7:4433-4446.
24. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release. 2008;132:164-170.
25. Jeong YI, Choi KC, Song CE. Doxorubicin release from core-shell type nanoparticles of poly(DL-lactide-co-glycolide)-grafted dextran. Arch Pharm Res. 2006;29:712-719.
26. Ichinose K, Tomiyama N, Nakashima M, et al. Antitumor activity of dextran derivatives immobilizing platinum complex (II). Anticancer Drugs. 2000;11:33-38.
27. Kim DH, Kim MD, Choi CW, et al. Antitumor activity of sorafenibincorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer. Nanoscale Res Lett. 2012;7:91.
28. van Manen HJ, van Apeldoorn AA, Verrijk R, van Blitterswijk CA, Otto C. Intracellular degradation of microspheres based on cross-linked dextran hydrogels or amphiphilic block copolymers: a comparative Raman microscopy study. Int J Nanomedicine. 2007;2:241-252.
29. Osterberg E, Bergström K, Holmberg K, et al. Protein-rejecting ability of surface-bound dextran in end-on and side-on configurations: comparison to PEG. J Biomed Mater Res. 1995;29:741-747.
30. Kaneo Y, Uemura T, Tanaka T, Kanoh S. Polysaccharides as drug carriers: biodisposition of fluorescein-labeled dextrans in mice. Biol Pharm Bull. 1997;20:181-187.
31. Mehvar R, Robinson MA, Reynolds JM. Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats. J Pharm Sci. 1994;83:1495-1499.
32. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. Carrier effects on antitumor activity and neurotoxicity of AZ10992, a paclitaxelcarboxymethyl dextran conjugate, in a mouse model. Biol Pharm Bull. 2008;31:223-230.
33. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J Control Release. 2007;117:40-50.
34. Johnson RP, Jeong YI, John JV, et al. Dual stimuli-responsive poly(N-isopropylacrylamide)-b-poly(L-histidine) chimeric materials for the controlled delivery of doxorubicin into liver carcinoma. Biomacromolecules. 2013;14:1434-1443.
35. Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folatemediated targeting. J Control Release. 2003;91:103-113.
36. Yang SR, Lee HJ, Kim JD. Histidine-conjugated poly(amino acid) derivatives for the novel endosomolytic delivery carrier of doxorubicin. J Control Release. 2006;114:60-68.